CoChat

LOXL2—A New Target in Antifibrogenic Therapy?

Open access
Puente, Angela, Fortea, Jose Ignacio, Cabezas, Joaquin, Arias Loste, Maria Teresa, Iruzubieta, Paula, Llerena, Susana, Huelin, Patricia, Fábrega, Emilio, Crespo, Javier · 2019 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Abstract

The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20071634

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The mechanism of hepatic fibrosis: progression and regression steps. Legend: PDGF: Platelet-derived growth factor; TGBβ: Transforming growth factor β; TNF: Tumor necrosis factor; IL-1β: Interleukin, HSC: Hepatic stellate cell; TRAIL: Related apoptosis-inducing ligand receptor; MMP: Metalloproteinase; ECM: Extracellular matrix. Adapted from: Trautwein C et al., Journal of Hepatology 2015.
Figure 1 The mechanism of hepatic fibrosis: progression and regression steps. Legend: PDGF: Platelet-derived growth factor; TGBβ: Transforming growth factor β; TNF: Tumor necrosis factor; IL-1β: Interleukin, HSC: Hepatic stellate cell; TRAIL: Related apoptosis-inducing ligand receptor; MMP: Metalloproteinase; ECM: Extracellular matrix. Adapted from: Trautwein C et al., Journal of Hepatology 2015.CC BY · PubMed Central
Figure 2 Effectors in liver fibrosis and potential therapeutic goals. Legend: Color coding: Red, profibrogenic mediators; blue, fibrolytic effectors; and green, potential therapies. Currently, there are several drugs in developement for treatment of liver fibrosis: ASK 1-inhibitor, selonsertib; pan-caspase inhibitor, emricasan; NO donors, statins; multikinase inhibitors, sorafenib, pacritinib; LOXL2, simtuzumab. Abbreviations: CXCR: Chemokine receptor; PPARγ: Peroxisome proliferator-activated receptors; CCL: Chemokine ligand; CBR: Cannabinoid receptor 1; ET-1: endothelin-1; ETAR: Endothelin A receptor; FXR: Farnesoid X receptor; Hh(R): Hedgehog (receptor); Int: Integrin; LPA1R: Lyso-phosphatidic acid receptor 1; NGFR: Nerve growth factor receptor; PTX2: Pentraxin 2; TRAIL R: Related apoptosis-inducing ligand receptor; CBR1: Carbonyl reductase 1; HGF: Hepatocyte growth factor; NGFR: Nerve growth factor receptor.
Figure 2 Effectors in liver fibrosis and potential therapeutic goals. Legend: Color coding: Red, profibrogenic mediators; blue, fibrolytic effectors; and green, potential therapies. Currently, there are several drugs in developement for treatment of liver fibrosis: ASK 1-inhibitor, selonsertib; pan-caspase inhibitor, emricasan; NO donors, statins; multikinase inhibitors, sorafenib, pacritinib; LOXL2, simtuzumab. Abbreviations: CXCR: Chemokine receptor; PPARγ: Peroxisome proliferator-activated receptors; CCL: Chemokine ligand; CBR: Cannabinoid receptor 1; ET-1: endothelin-1; ETAR: Endothelin A receptor; FXR: Farnesoid X receptor; Hh(R): Hedgehog (receptor); Int: Integrin; LPA1R: Lyso-phosphatidic acid receptor 1; NGFR: Nerve growth factor receptor; PTX2: Pentraxin 2; TRAIL R: Related apoptosis-inducing ligand receptor; CBR1: Carbonyl reductase 1; HGF: Hepatocyte growth factor; NGFR: Nerve growth factor receptor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 6

  1. Cabezas, 2017, Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral, Hepatology, 66, 218A
  2. Bosch, 2015, Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), Hepatology, 62, 120A
  3. Afdha, 2015, Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C, Hepatology, 62, 121A
  4. Bourliere, 2015, Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir/sofosbuvir (LDV/SOF)-based therapy, Hepatology, 62, 123A
  5. Puente, 2019, Influence of the metabolic syndrome on fibrosis regression regulated by LOXL2 after sustained virologycal response, Gastroenterol. Hepatol., 42, 123
  6. Tatal, 2013, Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase like 2, appears safe and well tolerated in patients with liver disease of diverse etiology, J. Hepatol., 58, S409

Cited by

See all 79

Metadata

Authors
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J.
Affiliations
  • Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain
  • Universidad de Cantabria (ES)
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-04-02
Volume
20
Issue
7
Pages
1634
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2933665664
Cited by
79
References
58
Citations by year
2026: 2 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 13 · 2019: 6
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCrea (University of Cantabria) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
LOXL2, liver fibrosis, antifibrotic therapy, liver cirrhosis, extracellular matrix, collagen deposition, hepatic stellate cells, Kupffer cells, monoclonal antibodies, fibrosis reversibility, portal pressure
MeSH terms
Animals, Humans, Liver Cirrhosis, Protein-Lysine 6-Oxidase, Models, Biological, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.